Moderate

Lymphocytosis work-up

lymphocytosis w/u · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A raised lymphocyte count is commonly reactive (viral infection) but may be clonal, most often chronic lymphocytic leukaemia in older adults. Age, persistence and film morphology guide whether flow cytometry is needed.

Red flags

  • Rapidly rising count with lymphadenopathy/hepatosplenomegaly
  • B symptoms and weight loss
  • Cytopenias (marrow failure or autoimmune in CLL)
  • Blasts suggesting acute leukaemia
  • Very high counts with hyperviscosity

Assessment

Differential diagnosis

  • Reactive/viral (EBV, CMV, pertussis)
  • Chronic lymphocytic leukaemia / small lymphocytic lymphoma
  • Other lymphoproliferative disorders (mantle cell, prolymphocytic)
  • Monoclonal B-cell lymphocytosis
  • Acute lymphoblastic leukaemia
  • Stress/post-splenectomy lymphocytosis

Investigations

  • FBC trend and blood film (smear cells suggest CLL; atypical lymphocytes suggest reactive)
  • Peripheral blood flow cytometry/immunophenotyping
  • Viral serology (EBV, CMV) in younger patients
  • LDH and examination for lymphadenopathy/splenomegaly
  • CLL markers (immunophenotype, FISH) if clonal
  • Marrow/imaging only if needed for staging

Management

  • Confirm lymphocytosis and assess chronicity (transient vs persistent)
  • Review age and clinical context - reactive causes dominate in the young, clonal disease in the elderly
  • Examine the film: smudge/smear cells point to CLL; reactive atypical lymphocytes to infection
  • Investigate viral causes in younger patients with systemic features
  • Perform flow cytometry for persistent or morphologically clonal lymphocytosis
  • Diagnose CLL when a characteristic clonal B-cell population meets threshold criteria
  • Distinguish monoclonal B-cell lymphocytosis (below CLL threshold) requiring only monitoring
  • Stage and risk-stratify confirmed CLL (clinical stage, FISH, IGHV, TP53)
  • Observe asymptomatic early CLL (watch-and-wait); treat on progression/symptoms
  • Arrange appropriate follow-up by cause

Drugs & doses

No drug for reactive lymphocytosis
CLL therapy when indicated: BTK inhibitors (e.g. acalabrutinib) or venetoclax-based regimens
Treat specific infection if identified

Disposition

Primary care follow-up for reactive causes; haematology for clonal lymphocytosis and CLL management.

Complications & pitfalls

  • Progression of CLL (cytopenias, infections, Richter transformation)
  • Autoimmune cytopenias in CLL
  • Immunoparesis and infection
  • Missed acute leukaemia
  • Tumour lysis with CLL treatment

Exam pearls

  • Smear (smudge) cells on the film are characteristic of CLL
  • Monoclonal B-cell lymphocytosis is below the CLL threshold and only needs monitoring
  • Reactive lymphocytosis is usually transient and resolves with the infection
  • Most early CLL is observed, not treated
  • Flow cytometry is the key test for persistent lymphocytosis

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.